EU's CHMP advises against use of J&J's Regranex in patients with cancer
This article was originally published in Scrip
Executive Summary
The EU's CHMP has concluded that Janssen-Cilag's (a Johnson & Johnson subsidiary) treatment for neuropathic skin ulcers in diabetic patients, Regranex (becaplermin), must not be used in patients who have any form of cancer as a precautionary measure.
You may also be interested in...
Market Intel: Intense Competition, Innovation Drive Healing Trends In Wound Care
The global advanced wound-care market is expected to reach $10.4bn by 2020, driven by massive competition, and forcing companies to innovate constantly to address the rising prevalence of chronic wound injuries, diabetic foot ulcers and burns. While regulatory and reimbursement challenges prevail, opportunities in this highly segmented market, in particular, in the advanced wound-dressings sector, are vast, with double-digit revenue growth potential.
P&G to co-promote Somaxon's Silenor in the US
Somaxon Pharmaceuticals and Procter & Gamble Pharmaceuticals are to co-promote Somaxon's insomnia drug Silenor (low-dose doxepin) in the US.
GSK's shingles vaccine begins Phase III studies
GlaxoSmithKline has begun the Phase III clinical trials programme for its adjuvanted vaccine candidate (GSK1437173A) against herpes zoster for the prevention of shingles.